Extended Data Fig. 2: Best reduction from baseline in target lesion (at end of CCRT phase) in patients from the nivolumab plus ipilimumab, nivolumab, and durvalumab arms. | Nature Cancer

Extended Data Fig. 2: Best reduction from baseline in target lesion (at end of CCRT phase) in patients from the nivolumab plus ipilimumab, nivolumab, and durvalumab arms.

From: Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

Extended Data Fig. 2: Best reduction from baseline in target lesion (at end of CCRT phase) in patients from the nivolumab plus ipilimumab, nivolumab, and durvalumab arms.The alternative text for this image may have been generated using AI.

Patients with a target lesion at baseline and ≥1 evaluable post-baseline tumor assessment prior to consolidation or who did not enter consolidation were included. Best reduction was maximum reduction in the sum of the diameters of target lesions (negative values mean true reduction; positive values mean increase only observed over time). Horizontal reference line indicates the 30% reduction consistent with RECIST v1.1 response. CCRT, concurrent chemoradiotherapy; RECIST v1.1, Response Evaluation Criteria in Solid Tumors Version1.1.

Source data

Back to article page